Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  nelarabine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Phase III Randomized Study of Standard Induction Chemotherapy With or Without Nelarabine or Rituximab in Patients With Newly Diagnosed, Previously Untreated Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Supportive care, Treatment
Status: Unknown
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Behavioral study, Treatment
Status: Closed
Age: 1 to under 31
Sponsor: NCI
Protocol IDs: NCI-2009-00307, CDR0000514500, COG-AALL0434, AALL0434, U10CA098543, NCT00408005
506U78 in Treating Patients With Refractory Hematologic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-01836, P9673, CCG-P9673, POG-9673, CDR0000065478, U10CA098543, NCT00002970
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01840, CLB-19801, SWOG-C19801, CDR0000066600, CALGB-19801, NCT00003545
506U78 in Treating Patients With Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Under 70
Sponsor: NCI
Protocol IDs: NCI-2012-02324, CALGB-59901, U10CA031946, CDR0000067687, NCT00005080
506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LN_GMALLE_2004_55, NCT00684619
S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: S0010, U10CA032102, SWOG-S0010, NCT00006020
Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Under 64
Sponsor: Pharmaceutical / Industry
Protocol IDs: PGA105446, NCT00406757
506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Phase: No phase specified
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000066994, CTEP-TRC-9701, CWRU-TRC-1499, TRC-9701, NCT00003837
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-01857, COG-AALL00P2, U10CA098543, CDR0000068620, AALL00P2, NCT00016302
Observational Study of Nelarabine in Children and Young Adults
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Completed
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111081, NCT00866671
Start Over